Contact
15 Jun 22
News
15 Jun 22

Biocomposites appoints Group Chief Financial Officer and New UK General Manager

Keele, UK, 15 June 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce two new appointments. Simon Greenhalgh has been appointed Group Chief Financial Officer (CFO) and Pete Webster takes up the position of UK General Manager.

Simon Greenhalgh brings extensive financial and international private equity experience following his role as Group CFO at Arlington Industries Group and previously Group Finance Director of independent IT distributor, Gamma Global Group. Arlington provided supply chain integration to global manufacturers in the aerospace and automotive sectors. During his tenure, Simon led on M&A investment and integration activities in supply chain companies internationally, working closely with the company’s US Private Equity sponsor.

Pete Webster joins from UK diagnostic company, BBI Group, where he was Director of Global Technical Operations for six years following his role as Director of Technical Engineering at Penn Pharmaceuticals. Pete brings considerable operational and strategic experience at a global level.

Commenting on the appointments, Michael Harris, CEO of Biocomposites, said: “We are delighted to have made these two important appointments. Simon and Pete will bring the financial and operational rigour needed to continue successfully expanding Biocomposites’ distributor footprint both locally and internationally while gaining new and enhanced product approvals which will enable more patients in more countries to gain access to our first-in-class products to achieve better outcomes.”

Contact for Media enquiries

Optimum Strategic Communications
Hollie Vile, Charlotte Hepburne-Scott, Zoe Bolt
Tel: +44 (0)20 3882 9621
biocomposites@optimumcomms.com

About Biocomposites

Biocomposites is an international medical devices company that engineers, manufactures, and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Canada, China, and India. Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry, and sports injuries. Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world. Please visit biocomposites.com to learn more.

Other news

Listed below is a list of the 4 most recent news updates made by Biocomposties


Visit our News & Events page

Library

Interested in other types of our content? See a list of some of our most recent below.

Explore Library